You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:protocol:olmesartan [11.27.2018] – [Other beneficial effects] sallieqhome:protocol:olmesartan [12.03.2018] – [Cardiovascular disease] sallieq
Line 146: Line 146:
   * act as an antiarrhythmic(({{pubmed>long:16094406}}))   * act as an antiarrhythmic(({{pubmed>long:16094406}}))
   * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed>long:16534230}}))   * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed>long:16534230}}))
 +  * This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy.  (({{pubmed>long:27086671}})) 
  
 <blockquote>Pharmacotherapy targeting the renin-angiotensin system [the mechanism of the ARBs] is one of the most effective means of reducing hypertension and cardiovascular morbidity.(({{pubmed>long:15531767}})) (({{pubmed>long:17984484}})) <blockquote>Pharmacotherapy targeting the renin-angiotensin system [the mechanism of the ARBs] is one of the most effective means of reducing hypertension and cardiovascular morbidity.(({{pubmed>long:15531767}})) (({{pubmed>long:17984484}}))
home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.